Global Natural Killer Cell Therapies Competitive Landscape, Technology, and Pipeline Analysis | DelveInsight

The report proffers a separate section for Natural Killer Augmenters including Natural Killer Cell Activators and Natural Killer Enhancers. The report proffers a separate section for Natural Killer Augmenters including Natural Killer Cell Activators and Natural Killer Enhancers. DelveInsight's NK Cell Therapies Market Landscape report covers30+ pipeline productsand20+ pharmaceutical and biotech companiesfunctional in the domain. Some of the key takeaways from the NK Cell...

The report proffers a separate section for Natural Killer Augmenters including Natural Killer Cell Activators and Natural Killer Enhancers.

DelveInsight's NK Cell Therapies Market Landscape report covers 30+ pipeline products and 20+ pharmaceutical and biotech companies functional in the domain.

Some of the key takeaways from the NK Cell Therapies Competitive landscape, Technology, and Pipeline Analysis  report: 

Get in touch for deep and rich insights into Natural Killer Cell Therapies Competitive landscape, Technology, and Pipeline Analysis

Natural Killer Cells

Natural Killer (NK) Cells are recognized for their ability to kill cancerous cells. These are lymphocytes hailing from the same family as that of T and B cells, however, NK cells are classified as group I Innate Lymphocytes (ILCs) and respond quickly to a wide variety of conditions including cancer. 

Natural Killer Cell Therapies in the Pipeline

haNK + avelumab + IL-15 Fusion Protein Combination Therapy: Nantkwest

NantKwest is developing an off-the-shelf natural killer cell-based therapeutic in combination with N-803 and ImmunityBio's IL-15 superagonist for the treatment of advanced refractory metastatic merkel cell carcinoma. The therapy leverages the company's hANK Cell Platform.

The drug is in Phase II of clinical development. A study titled "QUILT-3.063:A Phase 2 Study of Combination Therapy With an IL-15 Superagonist (N-803), Off-the-shelf CD16-targeted Natural Killer Cells (haNK), and Avelumab Without Cytotoxic Chemotherapy in Subjects with Merkel Cell Carcinoma (MCC) That Has Progressed on or After Treatment with a Checkpoint Inhibitor".  (NCT03853317) is currently active, not recruiting stage with an estimated enrollment of 43 participants, and is expected to be completed in March 2022.

Clinical Trials Description of NK Cell Therapies 

 

 

For more information on drug profiles, visit Natural Killer Cell Therapies Market Landscape Upcoming Trends 

Key Companies developing NK Cell Therapies 

Affimed, Altor Bioscience Corporation, AvidBiotic Corporation, Bristol-Myers Squibb, Celgene, CytoVac, Dynavax, Five Prime Therapeutics, Fortress Biotech, GamidaCell, Glycostem Therapeutics, iCell Gene Therapeutics, Innate Pharma, Multimmune GmbH, NantKwest, Nohla Therapeutics, PersonGen BioTherapeutics (Suzhou), Sorrento Therapeutics, Surface Oncology, ZIOPHARM Oncology, and others. 

NK Cells Therapeutic Assessment 

By Product 

By Stage 

By Route of Administration 

By Molecule Type 

By Stage and Molecule Type

By Stage and Route of Administration

By Stage and Product Type

Get a holistic view of NK Cell Therapies Market @Natural Killer Cell Therapies Competitive Landscape 

Scope of the report 

Know more of what's covered @ NK Cell Therapies Pipeline Analysis 

Table of Contents

 

 

Got queries? Want to know more about the report offerings? Get in touch @ Natural Killer Cell Therapies Pipeline Landscape and Emerging Trends 

Related Reports

Natural Killer T-Cell Lymphoma Market

DelveInsight's "Natural Killer T-Cell Lymphoma (NKTL) Market Insights, Epidemiology, and Market Forecast-2030" report.

Car-T Cell Therapy for Acute Lymphoblastic Leukemia Market

DelveInsight's "CAR T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL)- Market Insights and Market Forecast- 2030" report.

Car-T Cell Therapy for Multiple Myeloma Market

DelveInsight's 'CAR T-Cell Therapy for Multiple Myeloma-Market Insights and Market Forecast-2030' report.

Car-T Cell Therapy for Non-Hodgkins Lymphoma Market

DelveInsight's 'CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) Market Insights and Market Forecast-2030' report.

Adult T Cell Leukemia Lymphoma Market

DelveInsight's "Adult T-Cell Leukemia-Lymphoma Market Insights, Epidemiology, and Market Forecast-2030" report.

Chimeric Antigen Receptor Car-T Cell Immunotherapy Competitive Landscape Pipeline and Market Analysis

"Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Pipeline and Market Analysis, 2018", report. 

Advanced Renal Cell Carcinoma Market

DelveInsight's "Advanced Renal Cell Carcinoma (RCC) - Market Insights, Epidemiology, and Market Forecast-2030" report.

Anaplastic Lymphoma Kinase Non-Small Cell Lung Cancer Market

DelveInsight's 'Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) Market Insights, Epidemiology and Market Forecast-2030' report.

Angioimmunoblastic T Cell Lymphoma Market

DelveInsight's "Angioimmunoblastic T-Cell Lymphoma - Market Insights, Epidemiology, and Market Forecast-2030" report.

B Cell Chronic Lymphocytic Leukemia Market

DelveInsight's "B-Cell Chronic Lymphocytic Leukemia Market Insights, Epidemiology, and Market Forecast-2030" report.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur 
[email protected]
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg